IntelliPharmaCeutics International Stock Price, News & Analysis (TSE:I)

C$3.23 0.04 (1.25 %)
(As of 12/18/2017 12:59 PM ET)
Previous CloseC$3.19
Today's RangeC$3.15 - C$3.26
52-Week RangeC$1.78 - C$4.50
Volume7,625 shs
Average Volume16,872 shs
Market CapitalizationC$36.04 million
P/E RatioN/A
Dividend YieldN/A
Beta0.6

About IntelliPharmaCeutics International (TSE:I)

Intellipharmaceutics International Inc is a Canada-based pharmaceutical company engaged in the research, development and manufacture of controlled-release and targeted-release oral solid dosage drugs. Its Hypermatrix technology is a multidimensional controlled-release drug delivery platform that is applied to the development of a range of existing and new pharmaceuticals. Based on this technology platform, it has developed various drug delivery systems and a pipeline of products, and product candidates in various stages of development, in therapeutic areas that include neurology and cardiovascular. Its pipeline of products includes Rexista Oxycodone, Regabatin XR, Generic Focalin XR, Generic Effexor XR, Generic Protonix, Generic Glucophage XR, Generic Seroquel XR, Generic Lamictal XR, Generic Keppra XR, Generic Pristiq and Generic Ranexa. Its generic product candidates also include Trazodone hydrochloride extended-release tablets and Carvedilol phosphate extended-release capsules.

Receive I News and Ratings via Email

Sign-up to receive the latest news and ratings for I and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry N/A
Sub-IndustryN/A
SectorN/A
SymbolTSE:I
CUSIPN/A
WebN/A
Phone+1-416-7983001

Debt

Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A

Profitability

Trailing EPSC($0.44)
Net IncomeN/A
Net Margins-214.36%
Return on Equity-150,985.50%
Return on Assets-141.70%

Miscellaneous

EmployeesN/A
Outstanding Shares30,156,000

IntelliPharmaCeutics International (TSE:I) Frequently Asked Questions

What is IntelliPharmaCeutics International's stock symbol?

IntelliPharmaCeutics International trades on the Toronto Stock Exchange (TSX) under the ticker symbol "I."

How were IntelliPharmaCeutics International's earnings last quarter?

IntelliPharmaCeutics International Inc. (TSE:I) issued its earnings results on Monday, April, 14th. The company reported $0.10 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.03 by $0.07. The company had revenue of $5.14 million for the quarter, compared to analysts' expectations of $3.63 million. IntelliPharmaCeutics International had a negative return on equity of 150,985.50% and a negative net margin of 214.36%. View IntelliPharmaCeutics International's Earnings History.

When will IntelliPharmaCeutics International make its next earnings announcement?

IntelliPharmaCeutics International is scheduled to release their next quarterly earnings announcement on Friday, February, 9th 2018. View Earnings Estimates for IntelliPharmaCeutics International.

Who are some of IntelliPharmaCeutics International's key competitors?

Who are IntelliPharmaCeutics International's key executives?

IntelliPharmaCeutics International's management team includes the folowing people:

  • Isa Odidi Ph.D., Chairman of the Board, Chief Executive Officer
  • Amina Odidi Ph.D., President, Chief Operating Officer, Director
  • Andrew Patient, Chief Financial Officer
  • John N. Allport, Vice President - Legal Affairs and Licensing, Secretary, Director
  • Patrick N. Yat Ph.D., Vice President - Pharmaceutical Analysis and Chemistry
  • Kenneth Keirstead, Independent Director
  • Bahadur Madhani, Independent Director
  • Eldon R. Smith M.D., Independent Director (Age 75)

How do I buy IntelliPharmaCeutics International stock?

Shares of IntelliPharmaCeutics International and other Canadian stocks can be purchased through online brokerage accounts that support trading on the Toronto Stock Exchange (TSX). Brokers that permit trading on the TSX include Fidelity, Interactive Brokers, PennTrade and Charles Schwab.

What is IntelliPharmaCeutics International's stock price today?

One share of IntelliPharmaCeutics International stock can currently be purchased for approximately C$3.23.

How big of a company is IntelliPharmaCeutics International?

IntelliPharmaCeutics International has a market capitalization of C$36.04 million.

How can I contact IntelliPharmaCeutics International?

IntelliPharmaCeutics International's mailing address is 30 Worcester Rd, ETOBICOKE, ON M9W 5X2, Canada. The company can be reached via phone at +1-416-7983001.


MarketBeat Community Rating for IntelliPharmaCeutics International (I)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  34 (Vote Outperform)
Underperform Votes:  28 (Vote Underperform)
Total Votes:  62
MarketBeat's community ratings are surveys of what our community members think about IntelliPharmaCeutics International and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

IntelliPharmaCeutics International (TSE:I) Analyst Ratings History


No equities research coverage for this company has been tracked by MarketBeat

Earnings

IntelliPharmaCeutics International (TSE:I) Earnings History and Estimates Chart

Earnings by Quarter for IntelliPharmaCeutics International (TSE:I)

IntelliPharmaCeutics International (TSE I) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
2/9/2018        
4/14/2014C$0.03C$0.10C$3.63 millionC$5.14 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

IntelliPharmaCeutics International (TSE:I) Earnings Estimates

No earnings estimates for this company have been tracked by MarketBeat.com

Dividends

Dividend History for IntelliPharmaCeutics International (TSE:I)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

IntelliPharmaCeutics International (TSE I) Insider Trading and Institutional Ownership History

Insider Trades by Quarter for IntelliPharmaCeutics International (TSE:I)

IntelliPharmaCeutics International (TSE I) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
11/30/2015Penna Domenic DellaInsiderBuy3,510C$2.10C$7,371.00
11/25/2015Penna Domenic DellaInsiderBuy20,375C$1.87C$38,101.25
10/29/2015Bahadur MadhaniDirectorBuy1,000C$2.42C$2,420.00
(Data available from 1/1/2013 forward)

Headlines

IntelliPharmaCeutics International (TSE I) News Headlines

Source:
DateHeadline
Intellipharmaceutics (IPCI) Announces Receipt of Nasdaq NoticeIntellipharmaceutics (IPCI) Announces Receipt of Nasdaq Notice
www.streetinsider.com - December 5 at 12:35 PM
BRIEF-‍Armistice Capital Reports 5.2 Pct Passive Stake In Intellipharmaceutics InternationalBRIEF-‍Armistice Capital Reports 5.2 Pct Passive Stake In Intellipharmaceutics International
www.reuters.com - December 5 at 12:35 PM
Pro-Trader Daily: Corporate News Blog - Valeant Pharma Sells Sprout Pharmas Subsidiary Back to Original ShareholdersPro-Trader Daily: Corporate News Blog - Valeant Pharma Sells Sprout Pharma's Subsidiary Back to Original Shareholders
www.finanznachrichten.de - November 8 at 4:28 PM
Corporate News Blog - Valeant Pharma Sells Sprout Pharma’s Subsidiary Back to Original ShareholdersCorporate News Blog - Valeant Pharma Sells Sprout Pharma’s Subsidiary Back to Original Shareholders
finance.yahoo.com - November 8 at 4:28 PM
Intellipharmaceutics Announces Closing of US$4 Million Financing - GlobeNewswire (press release)Intellipharmaceutics Announces Closing of US$4 Million Financing - GlobeNewswire (press release)
globenewswire.com - October 13 at 7:28 PM
Intellipharmaceutics Announces Third Quarter 2017 Results - GlobeNewswire (press release)Intellipharmaceutics Announces Third Quarter 2017 Results - GlobeNewswire (press release)
globenewswire.com - October 11 at 5:10 AM
Intellipharmaceutics reports 3Q lossIntellipharmaceutics reports 3Q loss
finance.yahoo.com - October 10 at 7:07 PM
Intellipharmaceutics Announces Third Quarter 2017 ResultsIntellipharmaceutics Announces Third Quarter 2017 Results
www.nasdaq.com - October 10 at 7:07 PM
DEADLINE TODAY: Goldberg Law PC Announces a Securities Class Action Lawsuit against IntelliPharmaCeutics ... - PR Newswire (press release)DEADLINE TODAY: Goldberg Law PC Announces a Securities Class Action Lawsuit against IntelliPharmaCeutics ... - PR Newswire (press release)
www.prnewswire.com - September 30 at 9:40 PM
FDA Rejects IPCIs Painkiller, GNCA Bleeds On Herpes Vaccine News, PRQR AbuzzFDA Rejects IPCI's Painkiller, GNCA Bleeds On Herpes Vaccine News, PRQR Abuzz
www.rttnews.com - September 26 at 10:47 AM
BRIEF-Intellipharmaceutics receives complete response letter from FDA for Rexista NDABRIEF-Intellipharmaceutics receives complete response letter from FDA for Rexista NDA
www.reuters.com - September 25 at 6:16 PM
Intellipharmaceutics Announces Receipt of Nasdaq Notice - GlobeNewswire (press release)Intellipharmaceutics Announces Receipt of Nasdaq Notice - GlobeNewswire (press release)
globenewswire.com - September 20 at 9:03 PM
Intellipharmaceutics (IPCI) Names Andrew Patient as CFOIntellipharmaceutics (IPCI) Names Andrew Patient as CFO
www.streetinsider.com - September 1 at 8:02 PM
Cohen Milstein Sellers & Toll PLLC Announces Investigation of Intellipharmaceutics International, Inc.Cohen Milstein Sellers & Toll PLLC Announces Investigation of Intellipharmaceutics International, Inc.
www.businesswire.com - August 31 at 7:40 PM
SHAREHOLDER ALERT:  Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in IntelliPharmaCeutics International Inc. of Class Action Lawsuit and Upcoming Deadline – IPCISHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in IntelliPharmaCeutics International Inc. of Class Action Lawsuit and Upcoming Deadline – IPCI
feeds.benzinga.com - August 26 at 9:03 AM
IMPORTANT EQUITY ALERT: Lundin Law PC Announces Securities Class Action Lawsuit against ... - GlobeNewswire (press release)IMPORTANT EQUITY ALERT: Lundin Law PC Announces Securities Class Action Lawsuit against ... - GlobeNewswire (press release)
globenewswire.com - August 23 at 1:07 AM
IMPORTANT EQUITY ALERT: Lundin Law PC Announces Securities Class Action Lawsuit against IntelliPharmaCeutics International Inc. and Reminds Investors with Losses to Contact the FirmIMPORTANT EQUITY ALERT: Lundin Law PC Announces Securities Class Action Lawsuit against IntelliPharmaCeutics International Inc. and Reminds Investors with Losses to Contact the Firm
feeds.benzinga.com - August 21 at 4:26 PM
The Klein Law Firm Reminds Investors of Commencement of a Class Action Filed on Behalf of Intellipharmaceutics International Inc. Shareholders and a Lead Plaintiff Deadline of ...The Klein Law Firm Reminds Investors of Commencement of a Class Action Filed on Behalf of Intellipharmaceutics International Inc. Shareholders and a Lead Plaintiff Deadline of ...
www.businesswire.com - August 14 at 9:58 PM
SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action against IntelliPharmaCeutics ... - GlobeNewswire (press release)SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action against IntelliPharmaCeutics ... - GlobeNewswire (press release)
globenewswire.com - August 11 at 3:13 AM
SHAREHOLDER ALERT:  Pomerantz Law Firm Announces the Filing of a Class Action against IntelliPharmaCeutics International Inc. and Certain Officers – IPCISHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action against IntelliPharmaCeutics International Inc. and Certain Officers – IPCI
feeds.benzinga.com - August 10 at 3:01 PM
IPCI SHAREHOLDER ALERT: The Law Offices of Vincent Wong Notifies Investors of a Class Action Involving Intellipharmaceutics International Inc. and a Lead Plaintiff Deadline of ...IPCI SHAREHOLDER ALERT: The Law Offices of Vincent Wong Notifies Investors of a Class Action Involving Intellipharmaceutics International Inc. and a Lead Plaintiff Deadline of ...
www.businesswire.com - August 9 at 7:54 PM
INVESTOR ALERT: Levi & Korsinsky, LLP Reminds Shareholders It Filed a Complaint to Recover Losses Suffered by Investors in Intellipharmaceutics International Inc.INVESTOR ALERT: Levi & Korsinsky, LLP Reminds Shareholders It Filed a Complaint to Recover Losses Suffered by Investors in Intellipharmaceutics International Inc.
www.businesswire.com - August 8 at 7:22 PM
Robbins Arroyo LLP: IntelliPharmaCeutics International Inc. (IPCI) Misled Shareholders According to a Recently Filed Class ActionRobbins Arroyo LLP: IntelliPharmaCeutics International Inc. (IPCI) Misled Shareholders According to a Recently Filed Class Action
www.businesswire.com - August 7 at 7:10 PM
IMPORTANT EQUITY ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit against IntelliPharmaCeutics International Inc. and Encourages Investors with Losses to Contact the FirmIMPORTANT EQUITY ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit against IntelliPharmaCeutics International Inc. and Encourages Investors with Losses to Contact the Firm
feeds.benzinga.com - August 5 at 12:54 AM
The Klein Law Firm Notifies Investors of an Investigation Concerning Possible Violations of Federal Securities Laws by Intellipharmaceutics International Inc. (IPCI)The Klein Law Firm Notifies Investors of an Investigation Concerning Possible Violations of Federal Securities Laws by Intellipharmaceutics International Inc. (IPCI)
www.businesswire.com - August 4 at 7:56 PM
IMPORTANT EQUITY ALERT: Lundin Law PC Announces Securities Class Action Lawsuit against IntelliPharmaCeutics International Inc. and Encourages Investors with Losses to Contact the FirmIMPORTANT EQUITY ALERT: Lundin Law PC Announces Securities Class Action Lawsuit against IntelliPharmaCeutics International Inc. and Encourages Investors with Losses to Contact the Firm
feeds.benzinga.com - August 4 at 12:49 PM
INTELLIPHARMACEUTICS SHAREHOLDER ALERT BY FORMER...INTELLIPHARMACEUTICS SHAREHOLDER ALERT BY FORMER...
www.benzinga.com - August 2 at 8:16 PM
IMPORTANT INVESTOR ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit against IntelliPharmaCeutics International Inc. and Encourages Investors with Losses to ...IMPORTANT INVESTOR ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit against IntelliPharmaCeutics International Inc. and Encourages Investors with Losses to ...
www.businesswire.com - August 2 at 8:16 PM
INTELLIPHARMACEUTICS SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick ... - GlobeNewswire (press release)INTELLIPHARMACEUTICS SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick ... - GlobeNewswire (press release)
globenewswire.com - August 2 at 1:19 AM
INVESTOR ALERT: Goldberg Law PC Announces the Filing of a Securities Class Action Lawsuit against IntelliPharmaCeutics International Inc.INVESTOR ALERT: Goldberg Law PC Announces the Filing of a Securities Class Action Lawsuit against IntelliPharmaCeutics International Inc.
www.businesswire.com - August 1 at 8:16 PM
FDA panel votes against approving Intellipharmas opioid painkiller - ReutersFDA panel votes against approving Intellipharma's opioid painkiller - Reuters
www.reuters.com - July 28 at 3:01 AM
INVESTOR ALERT: Goldberg Law PC Announces an Investigation of IntelliPharmaCeutics International Inc. - Business Wire (press release)INVESTOR ALERT: Goldberg Law PC Announces an Investigation of IntelliPharmaCeutics International Inc. - Business Wire (press release)
www.businesswire.com - July 28 at 3:01 AM
Eagles Wings Clipped, FDA Panel Snubs IPCI, No Respite For CUR, MDXG On WatchEagle's Wings Clipped, FDA Panel Snubs IPCI, No Respite For CUR, MDXG On Watch
www.rttnews.com - July 27 at 2:13 AM
Intellipharmaceutics Provides Update on FDA Advisory Committees Meeting for Rexista™ (oxycodone hydrochloride extended release), an ...Intellipharmaceutics Provides Update on FDA Advisory Committees Meeting for Rexista™ (oxycodone hydrochloride extended release), an ...
globenewswire.com - July 27 at 2:13 AM
Intellipharmaceutics Provides Update on FDA Advisory Committees Meeting for Rexista™ (oxycodone hydrochloride ... - NasdaqIntellipharmaceutics Provides Update on FDA Advisory Committees Meeting for Rexista™ (oxycodone hydrochloride ... - Nasdaq
www.nasdaq.com - July 26 at 9:11 PM
Canadian Pharma Goes Before FDA Panel Wednesday on Tamper Resistant Opioid - TheStreet.comCanadian Pharma Goes Before FDA Panel Wednesday on Tamper Resistant Opioid - TheStreet.com
www.thestreet.com - July 25 at 8:00 PM
IntelliPharmaCeutics International - Very Low Downside And Huge Upside - Seeking AlphaIntelliPharmaCeutics International - Very Low Downside And Huge Upside - Seeking Alpha
seekingalpha.com - July 25 at 8:00 PM
UPDATE 1-FDA staff raise concerns about Intellipharmas opioid painkillerUPDATE 1-FDA staff raise concerns about Intellipharma's opioid painkiller
www.cnbc.com - July 25 at 4:20 AM
FDA staff raise concerns about Intellipharmas opioid painkiller - ReutersFDA staff raise concerns about Intellipharma's opioid painkiller - Reuters
www.reuters.com - July 24 at 11:17 PM
Intellipharmaceutics reports 2Q lossIntellipharmaceutics reports 2Q loss
www.cnbc.com - July 11 at 11:25 PM
Intellipharmaceutics Announces Second Quarter 2017 ResultsIntellipharmaceutics Announces Second Quarter 2017 Results
www.nasdaq.com - July 11 at 11:25 PM
Intellipharmaceutics International (IPCI) Jumps: Stock Up 19%Intellipharmaceutics International (IPCI) Jumps: Stock Up 19%
www.zacks.com - July 5 at 8:10 AM
Intellipharmaceutics (IPCI) Reports FDA Advisory Committee Meeting for Rexista to Review NDA on 7/26Intellipharmaceutics (IPCI) Reports FDA Advisory Committee Meeting for Rexista to Review NDA on 7/26
www.streetinsider.com - June 30 at 7:50 PM
Intellipharmaceutics Announces FDA Advisory Committee Meeting for Rexista™ (oxycodone hydrochloride extended release), an Abuse Deterrent ...Intellipharmaceutics Announces FDA Advisory Committee Meeting for Rexista™ (oxycodone hydrochloride extended release), an Abuse Deterrent ...
globenewswire.com - June 30 at 7:50 PM
BRIEF-Intellipharmaceutics announces FDA advisory committee meeting for rexistaBRIEF-Intellipharmaceutics announces FDA advisory committee meeting for rexista
www.reuters.com - June 30 at 7:50 PM
BRIEF-Intellipharmaceutics announces launch of generic seroquel XR by MallinckrodtBRIEF-Intellipharmaceutics announces launch of generic seroquel XR by Mallinckrodt
www.reuters.com - June 6 at 6:21 PM
Intellipharmaceutics Announces Launch of Generic Seroquel XR® by Mallinckrodt - GlobeNewswire (press release)Intellipharmaceutics Announces Launch of Generic Seroquel XR® by Mallinckrodt - GlobeNewswire (press release)
globenewswire.com - June 6 at 10:42 AM
BRIEF-Intellipharmaceutics International files for mixed shelf offering of up to $100 mlnBRIEF-Intellipharmaceutics International files for mixed shelf offering of up to $100 mln
www.reuters.com - May 27 at 4:33 AM
Intellipharmaceutics Reports on Launch of Additional Strengths of Generic Focalin XR® by Par Pharmaceutical - GlobeNewswire (press release)Intellipharmaceutics Reports on Launch of Additional Strengths of Generic Focalin XR® by Par Pharmaceutical - GlobeNewswire (press release)
globenewswire.com - May 24 at 5:41 PM
Intellipharmaceutics Reports Director Election Results - GlobeNewswire (press release)Intellipharmaceutics Reports Director Election Results - GlobeNewswire (press release)
globenewswire.com - April 19 at 11:31 AM

SEC Filings

IntelliPharmaCeutics International (TSE:I) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Financials are not available for this stock.

Chart

IntelliPharmaCeutics International (TSE I) Stock Chart for Monday, December, 18, 2017

Loading chart…

This page was last updated on 12/18/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.